




RECEIVED
JUN 26 2000
TECH CENTER 1600/2800
PATENT
JUN 26 2000
7/5/00

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on June 13, 2000


J. Michael Schiff

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: John C. Hiserodt

Art Unit: 1633

Serial No.: 09/162,648

Examiner: Carrie M. Stroup, Ph.D.

Filing Date: September 29, 1998

For: CANCER IMMUNOTHERAPY USING
ALLOSTIMULATED CELLS IN A
MULTIPLE SEQUENTIAL
IMPLANTATION STRATEGY

INFORMATION DISCLOSURE STATEMENT

PURSUANT TO 37 CFR § 1.97(c)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

06/21/2000 SSESHE1 00000045 09162648

01 FC:217
02 FC:126


435.00 OP
240.00 OP

PATENT
USSN 09/162,648
Docket: SEQ-2

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

A fee of **\$240** pursuant to 37 CFR § 1.17(c) is included in the enclosed check amount, for consideration of this Information Disclosure Statement under 37 CFR § 1.97(c).

Respectfully submitted,



J. Michael Schiff
Registration No. 40,253

808 Coleman Avenue, Suite 19
Menlo Park, CA 94025
Phone: 650-327-0960

June 13, 2000